Phenolic 1,4-Dihydropyridines: Hantzsch Synthesis, Molecular Docking, and Antioxidant Potential: A Review

References

[1] Singh DD, Yadav DK, Shin D. Next-generation antioxidants in cardiovascular disease: mechanistic insights and emerging therapeutic strategies. Antioxidants. 2026;15(2):164.

[2] Djafarou S, Alves E, Khodja IA, Seyhan G, Barut B, Harakat D, Mermer A, Pereira DM, Boulebd H. Design, synthesis and evaluation of anticancer and antioxidant properties of phenolic derivatives incorporating 4H-pyran/1,4-dihydropyridine/1,3-dihydropyrimidinone scaffolds. Eur J Med Chem. 2025;295:117803.

[3] Peng Y, Guo Y, Yang X, Liu Y, Xu X, Chen J, Liu X, Xie Z, Yu Z, Wu D, Chen Z. Novel idebenone derivatives attenuated oxidative stress injury and myocardial damage. Front Chem. 2025;13:1544616.

[4] Zhang Y, Ma X, Zhou X, Jiang K, Gu L, Li X, Zhu Y, Peng B. Green synthesis of 1,4-dihydropyridines through catalyst-free multicomponent Hantzsch reaction in an undergraduate teaching laboratory. J Chem Educ. 2025;102:1215–1222.

[5] Sazlı N, Karataş D. In silico design and computational elucidation of hypothetical resveratrol–curcumin hybrids as potential cancer pathway modulators. Pharmaceuticals. 2025;18(10):1473.

[6] Wei Y, Yu Z, Wang L, Li X, Li N, Bai Q, Wang Y, Li R, Meng Y, Xu H, Wang X, Dong Y, Huang Z, Zhang XC, Zhao Y. Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors. Nat Commun. 2024;15:2772.

[7] Kocak Aslan E, Lam K, Dengiz C, Denzinger K, Dicle Erdamar IY, Huang S, Zamponi GW, Wolber G, Gündüz MG. Synthesis, molecular modeling, DFT studies, and EPR analysis of 1,4-dihydropyridines as potential calcium channel blockers. J Mol Struct. 2024;1307:137983.

[8] Jin S, Kang PM. A systematic review on advances in management of oxidative stress-associated cardiovascular diseases. Antioxidants. 2024;13(8):923.

[9] Młynarska E, Hajdys J, Czarnik W, Fularski P, Leszto K, Majchrowicz G, Lisińska W, Rysz J, Franczyk B. The role of antioxidants in the therapy of cardiovascular diseases — a literature review. Nutrients. 2024;16(16):2587.

[10] Kwon G, Gibson KM, Bi L. Cutting-edge insights into oxidative stress and antioxidant therapy in cardiovascular health. Antioxidants. 2024;13(9):1034.

[11] Borade RM, Kale SB, Khirade PP, Jadhav KM, Pawar RP. Solvent-free synthesis of 1,4-dihydropyridine derivatives via Hantzsch reaction employing MgFe2O4 MNPs: an efficient and recyclable heterogeneous catalyst. J Inorg Organomet Polym Mater. 2024;34:1104–1120.

[12] Lago AFS, Benedicto DFC, da Silva L, Thomasi SS. 1,4-Dihydropyridine derivatives: an overview of synthesis conditions and biological tests. Curr Org Chem. 2023;27:1567–1610.

[13] Kaya MO, Demirci T, Ozdemir O, Calisir U, Sonmez F, Arslan M. Synthesis, inhibition effects, molecular docking and theoretical studies as paraoxonase-1 (PON1) inhibitors of novel 1,4-dihydropyridine substituted sulfonamide derivatives. Med Chem Res. 2023;32:841–855.

[14] Aggoun S, Bouchlaleg L, Belaidi S, Nour H, Abchir O, Chtita S, AlMogren MM, Hochlaf M. QSAR studies and molecular docking analysis of 1,4-dihydropyridines as calcium channel blockers using DFT and ANN methods. Research Square [Preprint]. 2023.

[15] Rezaei AR, Saberi S, Sepehri S. Synthesis, antileishmanial activity and molecular docking study of a series of dihydropyridine derivatives. Polycycl Aromat Compd. 2022;43:4640–4653.

[16] da Costa Cabrera D, Santa-Helena E, Leal HP, de Moura RR, Nery LEM, Gonçalves CAN, Russowsky D, Montes D'Oca MG. Synthesis and antioxidant activity of new lipophilic dihydropyridines. Bioorg Chem. 2019;84:1–16.

[17] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.

[18] Sharma MG, Rajani DP, Patel HM. Green approach for synthesis of bioactive Hantzsch 1,4-dihydropyridine derivatives based on thiophene moiety via multicomponent reaction. R Soc Open Sci. 2017;4:170006.

[19] Shaldam MA, Elhamamsy MH, Esmat EA, El-Moselhy TF. 1,4-Dihydropyridine calcium channel blockers: homology modeling of the receptor and assessment of structure activity relationship. ISRN Med Chem. 2014;2014:203518.

[20] Shahrisa A, Miri R, Esmati S, Saraei M, Mehdipour AR, Sharifi M. Synthesis and calcium channel antagonist activity of novel 1,4-dihydropyridine derivatives possessing 4-pyrone moieties. Med Chem Res. 2012;21:284–292.

[21] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.

[22] Triggle DJ. 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell Mol Neurobiol. 2003;23(3):293–303.

[23] Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM, Triggle DJ. 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J Med Chem. 1988;31(11):2103–2107.

[24] Bossert F, Meyer H, Wehinger E. 4-Aryldihydropyridines, a new class of highly active calcium antagonists. Angew Chem Int Ed Engl. 1981;20(9):762–769.

[25] Loev B, Goodman MM, Snader KM, Tedeschi R, Macko E. Hantzsch-type dihydropyridine hypotensive agents. J Med Chem. 1974;17(9):956–965.

[26] Blois MS. Antioxidant determinations by the use of a stable free radical. Nature. 1958;181:1199–1200.

[27] Hantzsch A. Ueber die Synthese pyridinartiger Verbindungen aus Acetessigäther und Aldehydammoniak. Justus Liebigs Ann Chem. 1882;1:215–260.

[28] World Health Organization. Global Report on Hypertension: The Race Against a Silent Killer. Geneva: World Health Organization; 2023.

[29] Furniss BS, Hannaford AJ, Smith PWG, Tatchell AR. Vogel's Textbook of Practical Organic Chemistry. 5th ed. Harlow: Longman Scientific & Technical; 1989.

[30] Yadav S, Chatterjee SJ. Hantzsch synthesis, molecular docking and antioxidant evaluation of novel phenolic substituted 1,4-dihydropyridine derivatives as potential calcium channel modulators (M.Pharm. synopsis). Jaunpur: S. N. College of Pharmacy, Dr. A.P.J. Abdul Kalam Technical University Lucknow; 2026.

[31] Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999;26(9–10):1231–1237.

[32] Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 1996;239(1):70–76.

[33] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.

[34] Anaikutti P, Makam P. 1,4-Dihydropyridine: synthetic advances, medicinal and insecticidal properties. RSC Adv. 2022;12(45):29253–29290.

[35] Al-Mathkuri TSF, Al-Jubori HMS, Majed AA, Moker MH, Santali E, Alnajjar R. Synthesis, docking, molecular dynamics, and biological evaluation of new hybrid dihydropyridine–pyrazole derivatives against breast cancer. Chem Pap. 2025. https://doi.org/10.1007/s11696-025-04581-9

[36] Al-Humaidi JY, Riyadh SM, Farag B, Zaki MEA, Abolibda TZ, Gomha SM. Synthesis of bis-thiazoles tethered 1,4-dihydropyridine and pyridine linkers via simple oxidation and their molecular docking as VEGFR-TK inhibitors. Curr Med Chem. 2025;32(9):1789–1802.

[37] Pansuriya K, Lalpara JN, Hadiyal SD, Dhaduk BB, Dubal GG. Phenylboronic acid catalyzed synthesis of polysubstituted 1,4-dihydropyridine derivatives as promising antioxidant agents correlated with molecular docking. Results Chem. 2022.

[38] Sidhom PA, El-Bastawissy E, Ibrahim MAA, Shawky AM, Salama A, El-Moselhy T. Mechanistic insight of synthesized 1,4-dihydropyridines as an antidiabetic sword against reactive oxygen species. J Med Chem. 2023;66:991–1010.

[39] Bandyopadhyay D, Maldonado S, Banik BK. A microwave-assisted bismuth nitrate-catalyzed unique route toward 1,4-dihydropyridines. Molecules. 2012;17(3):2643–2653.

[40] Sharma VK, Singh SK. Synthesis, utility and medicinal importance of 1,2- & 1,4-dihydropyridines. RSC Adv. 2017;7:2682–2732.

[41] Chen J, Yang J, Ma L, Li J, Shahzad N, Kim CK. Structure-antioxidant activity relationship of methoxy, phenolic hydroxyl, and carboxylic acid groups of phenolic acids. Sci Rep. 2020;10:2611.

[42] Platzer M, Kiese S, Tybussek T, Herfellner T, Schneider F, Schweiggert-Weisz U, Eisner P. Radical scavenging mechanisms of phenolic compounds: a quantitative structure-property relationship (QSPR) study. Front Nutr. 2022;9:882458.

[43] Kazmi S, Challa S, Alaparthi MD, Devi M I, Nagamalla SS, Priya EJ. Molecular docking analysis of calcium channel blockers with ALR2 and RAGE. Bioinformation. 2023;19(1):28–33.

@article{1724052,
      author = {Shikha Yadav, Swarup J. Chatterjee},
      title = {Phenolic 1,4-Dihydropyridines: Hantzsch Synthesis, Molecular Docking, and Antioxidant Potential: A Review},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {4},
      pages = {2538-2551},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1724052.pdf},
      abstract = {1,4-Dihydropyridines (DHPs), classically accessed through the century-old Hantzsch multicomponent reaction, remain one of the most clinically productive pharmacophores in cardiovascular medicine, underlying L-type calcium-channel blockers such as nifedipine, amlodipine, felodipine and nimodipine. Because oxidative stress is mechanistically intertwined with hypertension, endothelial dysfunction and atherosclerosis, a growing body of work has explored hybridising the DHP core with naturally occurring phenolic units (vanillin, syringaldehyde, protocatechualdehyde and related lignin-derived aldehydes) to generate dual-acting molecules capable of simultaneous calcium-channel modulation and free-radical scavenging. This review consolidates the classical and contemporary (2012–2026) literature on Hantzsch DHP synthesis — including green, catalytic and microwave-assisted variants — on the structural biology of the CaV1.2 dihydropyridine receptor site as resolved by cryo-electron microscopy, on structure-based molecular docking as a rational pre-synthetic screening tool, and on the physicochemical basis of phenolic antioxidant activity (hydrogen-atom transfer, single-electron transfer–proton transfer and sequential proton-loss electron-transfer mechanisms). Reported phenolic-DHP and related heterocyclic hybrids combining antioxidant, anticancer, antidiabetic and antimicrobial activity are critically compared, and the structure–activity principles that should guide the rational design of new dual-acting calcium-channel-modulating antioxidant candidates are synthesised. The review concludes by identifying gaps — particularly the scarcity of studies pairing structure-based CaV1.2 docking with standardised tri-assay (DPPH/ABTS/FRAP) antioxidant profiling of a single matched phenolic-DHP series — and outlines a feasible experimental and computational workflow for future investigation.},
      keywords = {1,4-dihydropyridine; Hantzsch reaction; calcium channel blocker; CaV1.2; molecular docking; phenolic antioxidant; DPPH/ABTS/FRAP; structure–activity relationship},
      month = {October},
  }